INmune Bio Receives R&D Rebates of Approximately $4.6 Million
Rhea-AI Summary
INmune Bio (NASDAQ: INMB) reported receiving a research and development cash rebate of approximately $4.2 million from Australia on July 30, 2026, in addition to about $0.4 million from the United Kingdom in June, for total rebates of roughly $4.6 million.
According to INmune Bio, after adjusting second-quarter operating cash flows to exclude the $0.4 million UK rebate, the combined rebate proceeds exceeded net cash used in operating activities for the quarter. The company said the non-dilutive funding strengthens its balance sheet and extends its cash runway as it advances its late-stage platforms CORDStrom™ (Ebstrocel™) toward regulatory filings and XPro1595™ toward an integrated Phase 2b/3 program in early Alzheimer’s disease.
Positive
- R&D rebates of ~$4.6 million received from Australia and UK
- Combined rebates exceeded Q2 net cash used in operations after adjustment
- Rebates are non-dilutive cash, avoiding additional equity issuance
- Additional liquidity supports CORDStrom™ regulatory filings in UK/EU/US
- Supports XPro1595™ Phase 2b/3 registrational program in early Alzheimer’s
Negative
- None.
News Explained
The July 31 rebate disclosure adds cash without an equity issuance; against the
Sources and calculations
- INmune Bio R&D rebate announcement (2026-07-31)
- INmune Bio first-quarter financials (2026-03-31)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $21,358,000 / ($3,403,000 / 90) = [object Object]
News Market Reaction – INMB
In the Jul 31 session, INMB declined 1.13%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 20 | Manufacturing milestone | Positive | +4.7% | Commercial manufacturing milestone supported planned global CORDStrom registration filings. |
| Jul 15 | Preclinical Alzheimer’s data | Positive | +2.5% | XPro1595 prevented Alzheimer’s-related pathology and memory loss in a preclinical study. |
| Jul 09 | Phase 2 imaging data | Positive | +4.1% | Phase 2 imaging data showed statistically significant white matter myelin changes. |
| Jul 01 | Patent application advancement | Positive | +3.1% | CORDStrom patent application advanced into the U.S. national phase. |
| Jun 25 | MHRA PIP approval | Positive | +10.4% | UK MHRA approved the Pediatric Investigation Plan for Ebstrocel. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news events in the platform record all showed positive 24-hour reactions, indicating consistent alignment rather than divergence.
Key Terms
non-dilutive cash financial
marketing authorization application regulatory
biologics license application regulatory
fast track designation regulatory
allogeneic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately
“These rebates are a meaningful financial milestone for INmune Bio and our shareholders,” said David Moss, Chief Executive Officer of INmune Bio. “Receiving approximately
The rebates were generated through established government programs designed to support qualifying research and development conducted in the UK and Australia. They reflect eligible expenditures related to the Company’s clinical-development, manufacturing and regulatory activities in those jurisdictions.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving beyond early-stage exploration, the Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.
INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:
- CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
- XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF (sTNF) to eliminate neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.
To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, the amount, timing, accounting treatment and financial impact of R&D rebates; anticipated cash balances, cash burn, net cash generation and cash runway; trial results and data; the timing of key milestones; future plans or expectations; and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body, and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to foreign exchange rates; finalization of the Company’s financial statements; the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contacts:
David Moss
Chief Executive Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
